Carbonic anhydrase inhibitors: Binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 6, 2007, Pages 1726-1731

  Fiore, Anna Di ^a   Scozzafava, Andrea ^b   Winum, Jean Yves ^c   Montero, Jean Louis ^c   Pedone, Carlo ^a   Supuran, Claudiu T ^b   De Simone, Giuseppina ^a  

^a CNR   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIV MONTPELLIER   (France)

Author keywords

Antiglaucoma drug; Carbonic anhydrase; Glycosyl sulfanilamide; Sulfonamide; X ray crystallography

Indexed keywords

ANTIGLAUCOMA AGENT; CARBONATE DEHYDRATASE INHIBITOR; ENZYME INHIBITOR; GLYCINE; GLYCOSYLSULFANILAMIDE DERIVATIVE; ISOENZYME; METAL ION; N (4 SULFAMOYLPHENYL) ALPHA DEXTRO GLUCOPYRANOSYLAMINE; PROLINE; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME BINDING; HUMAN; HYDROPHILICITY;

BINDING SITES; CARBOHYDRATES; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE INHIBITORS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; FRUCTOSE; GLAUCOMA; HUMANS; HYDROGEN BONDING; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; SULFANILAMIDES;

EID: 33847116270     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.12.099     Document Type: Article

References (38)

1. Pastorekova S., Parkkila S., and Zavada J. Adv. Clin. Chem. 42 (2006) 167
2. Scozzafava A., Mastrolorenzo A., and Supuran C.T. Expert Opin. Ther. Patent 16 (2006) 1627
3. In: Supuran C.T., Scozzafava A., and Conway J. (Eds). Carbonic Anhydrase-Its Inhibitors and Activators (2004), CRC, Boca Raton, New York, London 1
4. Pastorekova S., Parkkila S., Pastorek J., and Supuran C.T. J. Enzyme Inhib. Med. Chem. 19 (2004) 199
5. Supuran C.T., Scozzafava A., and Casini A. Development of Sulfonamide Carbonic Anhydrase Inhibitors. In: Supuran C.T., Scozzafava A., and Conway J. (Eds). Carbonic Anhydrase-Its Inhibitors and Activators (2004), CRC, Boca Raton 67
6. Supuran C.T., Scozzafava A., and Casini A. Med. Res. Rev. 23 (2003) 146
7. Scozzafava A., Mastrolorenzo A., and Supuran C.T. Expert Opin. Ther. Patent 14 (2004) 667
8. Winum J.Y., Montero J.L., Scozzafava A., and Supuran C.T. Mini-Rev. Med. Chem. 6 (2006) 921
9. Winum J.Y., Scozzafava A., Montero J.L., and Supuran C.T. Med. Res. Rev. 25 (2005) 186
10. Winum J.-Y., Scozzafava A., Montero J.-L., and Supuran C.T. Expert Opin. Ther. Patent 16 (2006) 27
11. Winum J.-Y., Scozzafava A., Montero J.-L., and Supuran C.T. Med. Res. Rev. 26 (2006) 767
12. Thiry A., Dogne J.M., Masereel B., and Supuran C.T. Trends Pharmacol. Sci. 27 (2006) 566
13. Alterio V., Vitale R.M., Monti S.M., Pedone C., Scozzafava A., Cecchi A., De Simone G., and Supuran C.T. J. Am. Chem. Soc. 128 (2006) 8329
14. Weber A., Casini A., Heine A., Kuhn D., Supuran C.T., Scozzafava A., and Klebe G. J. Med. Chem. 47 (2004) 550
15. Menchise V., De Simone G., Alterio V., Di Fiore A., Pedone C., Scozzafava A., and Supuran C.T. J. Med. Chem. 48 (2005) 5721
16. De Simone G., Di Fiore A., Menchise V., Pedone C., Antel J., Casini A., Scozzafava A., Wurl M., and Supuran C.T. Bioorg. Med. Chem. Lett. 15 (2005) 2315
17. Casini A., Antel J., Abbate F., Scozzafava A., David S., Waldeck H., Schafer S., and Supuran C.T. Bioorg. Med. Chem. Lett. 13 (2003) 841
18. Abbate F., Casini A., Owa T., Scozzafava A., and Supuran C.T. Bioorg. Med. Chem. Lett. 14 (2004) 217
19. Abbate F., Supuran C.T., Scozzafava A., Orioli P., Stubbs M., and Klebe G. J. Med. Chem. 45 (2002) 3583
20. Boriack P.A., Christianson D.W., Kingery-Wood J., and Whitesides G.M. J. Med. Chem. 38 (1995) 2286
21. Stams T., Chen Y., Boriack-Sjodin P.A., Hurt J.D., Liao J., May J.A., Dean T., Laipis P., Silverman D.N., and Christianson D.W. Protein Sci. 7 (1998) 556
22. Kim C.Y., Chang J.S., Doyon J.B., Baird T.T., Fierke C.A., Jain A., and Christianson D.W. J. Am. Chem. Soc. 122 (2000) 12125
23. Whittington D.A., Waheed A., Ulmasov B., Shah G.N., Grubb J.H., Sly W.S., and Christianson D.W. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9545
24. Vidgren J., Svensson A., and Liljas A. Int. J. Biol. Macromol. 15 (1993) 97
25. Abbate F., Winum J.Y., Potter B.V., Casini A., Montero J.L., Scozzafava A., and Supuran C.T. Bioorg. Med. Chem. Lett. 14 (2004) 231
26. Lloyd M.D., Pederick R.L., Natesh R., Woo L.W., Purohit A., Reed M.J., Acharya K.R., and Potter B.V. Biochem. J. 385 (2005) 715
27. Lloyd M.D., Thiyagarajan N., Ho Y.T., Woo L.W., Sutcliffe O.B., Purohit A., Reed M.J., Acharya K.R., and Potter B.V. Biochemistry 44 (2005) 6858
28. Gruneberg S., Stubbs M.T., and Klebe G. J. Med. Chem. 45 (2002) 3588
29. Antel J., Weber A., Sotriffer C.A., and Klebe G. Multiple binding modes observed in X-ray structures of carbonic anhydrase inhibitor complexes and other systems: Consequences for structure-based drug design. In: Supuran C.T., Scozzafava A., and Conway J. (Eds). Carbonic Anhydrase-Its Inhibitors and Activators (2004), CRC, Boca Raton 45-65
30. Christianson D.W. Acc. Chem. Res. 38 (2005) 191
31. Shin H., Cama E., and Christianson D.W. J. Am. Chem. Soc. 126 (2004) 10278
32. Svastova E., Hulikova A., Rafajova M., Zat'ovicova M., Gibadulinova A., Casini A., Cecchi A., Scozzafava A., Supuran C.T., Pastorek J., and Pastorekova S. FEBS Lett. 577 (2004) 439
33. Cecchi A., Hulikova A., Pastorek J., Pastorekova S., Scozzafava A., Winum J.-Y., Montero J.-L., and Supuran C.T. J. Med. Chem. 48 (2005) 4834
34. Winum J.-Y., Casini A., Mincione F., Starnotti M., Montero J.-L., Scozzafava A., and Supuran C.T. Bioorg. Med. Chem. Lett. 14 (2004) 225
35. Wilkinson B.L., Bornaghi L.F., Houston T.A., Innocenti A., Supuran C.T., and Poulsen S.A. J. Med. Chem. 49 (2006) 6539
36. 20 Clear density for the inhibitor was observed in the difference map after this single round of refinement (R-free = 0.335; R-factor = 0.311). Introduction of the inhibitor and alternating cycles of addition of water, manual rebuilding and energy minimization and B-factor refinement gave a final model with R-free = 0.197 and R-factor = 0.176. The statistics for refinement are summarized in Table 1. Coordinates and structure factors have been deposited in the Brookhaven Protein Data Bank (Accession code 2HL4)
37. Brünger A.T., Adams P.D., Clore G.M., De Lano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., and Warren G.L. Acta Crystallogr. Sect. D 54 (1998) 905
38. Otwinowski Z., and Minor W. Meth. Enzymol. 276 (1997) 307